Complement C1 inhibitor protein: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz mNo edit summary |
mNo edit summary |
||
| Line 5: | Line 5: | ||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 11:01, 31 July 2024
In medicine and immunology, complement C1 inhibitor protein (C1 esterase inhibitor or C1 INH protein) is an "endogenous serine protease inhibitor (serpins). It is a 105-kDa plasma glycoprotein, encoded by C1NH gene and produced primarily by the liver and monocytes. It inhibits a broad spectrum of proteases, including the complement c1r and the complement C1S proteases of the classical complement pathway, and the mannose-binding protein-associated serine proteases. C1-INH-deficient individuals suffer from hereditary angioedema".[1]
Angioedema due to deficiency of complement C1 inhibitor protein may also be acquired.[2][3]
References
- ↑ Anonymous (2024), Complement C1 inhibitor protein (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Markovic SN, Inwards DJ, Frigas EA, Phyliky RP (January 2000). "Acquired C1 esterase inhibitor deficiency". Ann. Intern. Med. 132 (2): 144–50. PMID 10644276. [e]
- ↑ Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A (July 2003). "Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies". Medicine (Baltimore) 82 (4): 274–81. DOI:10.1097/01.md.0000085055.63483.09. PMID 12861105. Research Blogging.